CEO Stephen Griffin stated that the company is sharpening its execution with three strategic priorities: “Our top priority is accelerating sustainable revenue growth with the commercial channel as the ...
Anika Therapeutics reports Q1 2025 revenue of $26.2 million, with an 18% rise in Commercial Channel revenue. Anika Therapeutics reported a first quarter 2025 revenue of $26.2 million, reflecting a 10% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results